Qing Chang

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 7

Top Topics

Photodynamic Therapy

Ejection Fraction

Prognostic Factors

Top Venues

Journal of ophthalmology

Eye (London, England)

The British journal of ophthalmology

This page only lists publications with an associated author ORCID identifier.

Publications

Jia Yu, Lei Li, Chunhui Jiang, Qing Chang, Ge-Zhi Xu
Clinical Characteristics of Pregnancy-Associated Central Serous Chorioretinopathy in the Chinese Population. Journal of ophthalmology 2021 (2021)
Jia Yu, Xiaofeng Ye, Lei Li, Chunhui Jiang, Qing Chang, Ge-Zhi Xu
Threshold thickness of foveal outer nuclear layer associated with outcomes of photodynamic therapy in central serous chorioretinopathy. Eye (London, England) (2021)
Feng-Juan Gao, Dan-Dan Wang, Fang Chen, Hao-Xiang Sun, Fang-Yuan Hu, Ping Xu, Jiankang Li, Wei Liu, Yu-He Qi, Wei Li, Ming Wang, Shenghai Zhang, Ge-Zhi Xu, Qing Chang, Ji-Hong Wu
Prevalence and genetic-phenotypic characteristics of patients with USH2A mutations in a large cohort of Chinese patients with inherited retinal disease. The British journal of ophthalmology 105 (1) (2020)
Jia Yu, Lei Li, Chunhui Jiang, Qing Chang, Qi Zhao
Inter- and Intra-individual Variations in Foveal Outer Nuclear Layer Thickness and Their Associations with Clinical Characteristics in a Healthy Chinese Population. Journal of ophthalmology 2020 (2020)
Jia Yu, Xiaofeng Ye, Lei Li, Qing Chang, Chunhui Jiang
Relationship between photoreceptor layer changes before half-dose photodynamic therapy and functional and anatomic outcomes in central serous chorioretinopathy. Eye (London, England) 35 (3) (2020)
Jia Yu, Gezhi Xu, Qing Chang, Xiaofeng Ye, Lei Li, Chunhui Jiang, Qi Zhao
Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy. Journal of ophthalmology 2019 (2019)
Fenghua Wang, Yuan-Zhi Yuan, Ling Wang, Xiaofeng Ye, Jingke Zhao, Mengxi Shen, Qi Zhang, Ding Xu, Guo-You Qin, Wei Zhang, Fei Yuan, Qing Chang, Pei-Quan Zhao, Fang Wang, Xiaodong Sun
One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial. Journal of ophthalmology 2019 (2019)